Decreased peak bone mass is associated with a 3-bp deletion/insertion of the CYP19 intron 4 polymorphism: Preliminary data from the GOOS study

Journal of Endocrinological Investigation

Volumn 30, Issue 6, 2007, Pages 465-469

  Kastelan, D ^a   Grubic, Z ^a   Kraljevic, I ^a   Duric, K ^a   Kardum, I ^a   Dusek, T ^a   Stingl, K ^a   Giljevic, Z ^a   Kerhin Brkljacic, V ^a   Suchanek, E ^a   Korsic, M ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Aromatase; CYP19; Genetics; Peak bone mass; TTTA polymorphism

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; AROMATASE; ESTRADIOL; OSTEOCALCIN; TESTOSTERONE;

ADULT; ALLELE; ARTICLE; BONE DENSITY; BONE MASS; BONE REMODELING; CONTROLLED STUDY; CROATIA; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMUR NECK; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HIP; HUMAN; INTRON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; SPINE; TESTOSTERONE BLOOD LEVEL;

EID: 34848925430     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346329     Document Type: Article

References (23)

1. Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002, 87: 2460-6.
2. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC Jr. Genetic determinants of bone mass in adult women: A reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res 1991, 6: 561-7.
3. Morrison NA, Yeoman R, Kelly PJ, Eisman JA. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Natl Acad Sci USA 1992, 89: 6665-9.
4. Grant SF, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 site in the collagen type 1 alpha 1 gene. Nat Genet 1996, 14: 203-5.
5. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H. Association of bone mineral density with polymorphisms of the estrogen receptor gene. J Bone Miner Res 1996, 11: 306-11.
6. Sowers M, Willing M, Burns T, et al. Genetic markers, bone mineral density, and serum osteocalcin levels. J Bone Miner Res 1999, 14: 1411-9.
7. Hosoi T, Miyao M, Inoue S, et al. Association study of parathyroid hormone gene polymorphism and bone mineral density in Japanese postmenopausal women. Calcif Tissue Int 1999, 64: 205-8.
8. Lorentzon M, Swanson C, Eriksson AL, Mellström D, Ohlsson C. Polymorphism in the aromatase gene predict areal BIVID as a result of affected cortical bone size: the GOOD study. J Bone Miner Res 2006, 21: 332-9.
9. 7 allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur J Cancer 2002, 38: 1911-6.
10. Dialyna I, Tzanakakis G, Dolapsakis G, Tsatsakis A. Atetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides. Toxicol Lett 2004, 151: 267-71.
11. n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res 2003, 23: 4941-6.
12. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994, 331: 1056-61.
13. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995, 80: 3689-98.
14. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000, 106: 1553-60.
15. Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 2001, 86: 2869-74.
16. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol (Oxf) 1998, 49: 803-9.
17. Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004, 89: 2803-10.
18. Zarrabeitia A, Zarrabeitia MT, Valero C, Gonzalez-Macias J, Riancho JA. Age-related influence of common aromatase gene polymorphisms on bone mass of healthy men. Bone 2004, 35: 243-8.
19. Dick IM, Devine A, Prince RL. Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women. Am J Physiol Endocrinol Metab 2005, 288: E989-95.
20. Kastelan D, Kujundzic Tiljak M, Kraljevic I, Kardum I, Giljevic Z, Korsic M. Calcaneus ultrasound in males-normative data in the Croatian population (ECUM study). J Endocrinol Invest 2006, 29: 221-5.
21. Baghaei F, Rosmond R, Westberg L, et al. The CYP19 gene association with androgens and abdominal obesity in premenopausal women, Obes Res 2003, 11: 578-85.
22. Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000, 19: 1329-33.
23. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999, 79: 456-63.